Fiamma Buttitta

Prof. Fiamma Buttitta


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Antonio MarchettiAntonio Marchetti
Antonio Marchetti
MGMaela Del Grammastro
Maela Del Grammastro
LFLara Felicioni
Lara Felicioni
SMSara Malatesta
Sara Malatesta
GFGiampaolo Filice
Giampaolo Filice
FBFiamma Buttitta
Fiamma Buttitta
Assessment of EGFR mutation in non-small cell lung cancer (NSCLC) patients is mandatory for optimization of pharmacologic treatment. In this respect, mutation analysis of circulating tumor cells (CTCs) may be desirable since they may provide real-time information on patient's disease status. Blood samples were collected from 37 patients enrolled in the TRIGGER study, a prospective phase II multi-center trial of erlotinib treatment in advanced NSCLC patients with activating EGFR mutations in tumor tissue. 10 CTC preparations from breast cancer patients without EGFR mutations in their primary tumors and 12 blood samples from healthy subjects were analyzed as negative controls. CTC preparations, obtained by the Veridex CellSearch System, were subjected to ultra-deep next generation sequencing (NGS) on the Roche 454 GS junior platform. CTCs fulfilling all Veridex criteria were present in 41% of the patients examined, ranging in number between 1 and 29. In addition to validated CTCs, potential neoplastic elements were seen in 33 cases. These included cells not fulfilling all Veridex criteria (also known as “suspicious objects”) found in 5 (13%) of 37 cases, and isolated or clustered large naked nuclei with irregular shape observed in 33 (89%) cases. EGFR mutations were identified by NGS in CTC preparations of 31 (84%) patients, corresponding to those present in matching tumor tissue. Twenty-five (96%) of 26 deletions at exon 19 and 6 (55%) of 11 mutations at exon 21 were detectable (P = 0.005). In 4 (13%) cases, multiple EGFR mutations, suggesting CTC heterogeneity, were documented. No mutations were found in control samples. We report for the first time that the CellSearch System coupled with NGS is a very sensitive and specific diagnostic tool for EGFR mutation analysis in CTC preparations with potential clinical impact.

1 April 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
AMAntonio Marchetti
Antonio Marchetti
ALAlessia Di Lorito
Alessia Di Lorito
MPMaria Vittoria Pace
Maria Vittoria Pace
MIManuela Iezzi
Manuela Iezzi
LFLara Felicioni
Lara Felicioni
FBFiamma Buttitta
Fiamma Buttitta

27 July 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Antonio MarchettiAntonio Marchetti
Antonio Marchetti
MGMaela Del Grammastro
Maela Del Grammastro
GFGiampaolo Filice
Giampaolo Filice
LFLara Felicioni
Lara Felicioni
GRGiulio Rossi
Giulio Rossi
FBFiamma Buttitta
Fiamma Buttitta
Microdeletions at exon 19 are the most frequent genetic alterations affecting the Epidermal Growth Factor Receptor (EGFR) gene in non-small cell lung cancer (NSCLC) and they are strongly associated with response to treatment with tyrosine kinase inhibitors. A series of 116 NSCLC DNA samples investigated by Sanger Sequencing (SS), including 106 samples carrying exon 19 EGFR deletions and 10 without deletions (control samples), were subjected to deep next generation sequencing (NGS). All samples with deletions at SS showed deletions with NGS. No deletions were seen in control cases. In 93 (88%) cases, deletions detected by NGS were exactly corresponding to those identified by SS. In 13 cases (12%) NGS resolved deletions not accurately characterized by SS. In 21 (20%) cases the NGS showed presence of complex (double/multiple) frameshift deletions producing a net in-frame change. In 5 of these cases the SS could not define the exact sequence of mutant alleles, in the other 16 cases the results obtained by SS were conventionally considered as deletions plus insertions. Different interpretative hypotheses for complex mutations are discussed. In 46 (43%) tumors deep NGS showed, for the first time to our knowledge, subpopulations of DNA molecules carrying EGFR deletions different from the main one. Each of these subpopulations accounted for 0.1% to 17% of the genomic DNA in the different tumors investigated. Our findings suggest that a region in exon 19 is highly unstable in a large proportion of patients carrying EGFR deletions. As a corollary to this study, NGS data were compared with those obtained by immunohistochemistry using the 6B6 anti-mutant EGFR antibody. The immunoreaction was E746-A750del specific. In conclusion, NGS analysis of EGFR exon 19 in NSCLCs allowed us to formulate a new interpretative hypothesis for complex mutations and revealed the presence of subpopulations of deletions with potential pathogenetic and clinical impact.

1 May 2002
Verified
Journal Article
Closed access
Antonio MarchettiAntonio Marchetti
Antonio Marchetti
NTnicola tinari
nicola tinari
FBFiamma Buttitta
Fiamma Buttitta
ACAntonio Chella
Antonio Chella
CACarlo Alberto Angeletti
Carlo Alberto Angeletti
SIStefano Iacobelli
Stefano Iacobelli

1 September 2003
Verified
Journal Article
Closed access
CPCaterina Pellegrini
Caterina Pellegrini
MFMonica Falleni
Monica Falleni
Antonio MarchettiAntonio Marchetti
Antonio Marchetti
BCBarbara Cassani
Barbara Cassani
MMMonica Miozzo
Monica Miozzo
SBSilvano Bosari
Silvano Bosari

1 September 2001 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
Antonio MarchettiAntonio Marchetti
Antonio Marchetti
FBFiamma Buttitta
Fiamma Buttitta
GBGloria Bertacca
Gloria Bertacca
KZKatia Zavaglia
Katia Zavaglia
GBGeneroso Bevilacqua
Generoso Bevilacqua
FMFelice Mucilli
Felice Mucilli